96%* of radiologists agree with Volpara’s assessment of non-dense or dense.
*Data on company file. Analysis from 36,642 cases across four clinics.
When input to the TC8 model Volpara has been shown to change the risk of 4.5%* of patients.
*Destounis, S. V., et al. (2021, November–December). Impact on risk categorization with inclusion of mammographic density in the Tyrer-Cuzick model. Abstract presented at the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, Chicago, IL.
Volpara’s FDA-cleared TruDensity™ algorithm powers Scorecard, a breast density assessment software that delivers consistent, volumetric insights. It provides clinicians with consistent, objective data to support earlier cancer detection and supplemental imaging recommendations.
As the only breast density assessment software validated for use with Tyrer-Cuzick v8 (TC8), it provides precise data to support lifetime breast cancer risk assessment to help identify patients who may need additional imaging or preventive measures.
*Requires additional software purchase, not available in all countries.
By providing an objective density score, we help clinicians determine when supplemental screening methods may be necessary, ensuring that high-risk patients receive the right care at the right time.
Scorecard is a trusted standard for breast density analysis, used in over 4,800 hospitals and backed by 400+ studies.
“I can’t even remember the last time I disagreed with the software… it has truly made a difference in the care we provide patients.”
“We have found Volpara to decrease inter and intraobserver variation in breast density determination thereby optimizing the care of our patients.”
Stay informed with the latest research, product updates, and global partnerships driving innovation in AI-powered cancer screening.
Explore resources to support accurate, consistent breast density assessment.
